Table 4.

Reversal Study 2: Time Course of Reversal of Distal Tibial MNCV Deficits after 2 and 4 Weeks of Treatment with the SDI or the ARI (Zopolrestat) Initiated after 6 Weeks of Untreated Diabetes (No Rx)

	MNCV
	6 wk (No Rx)	8 wk (2 wk Rx)	10 wk (4 wk Rx)	BF	VAP	Sorbitol	Fructose	Myoinositol
Control	58.0 ± 5.7	59.9 ± 4.5	58.9 ± 3.3	72 ± 10	76 ± 12	238 ± 43	1,000 ± 177	5,953 ± 2,125
Diabetic	49.7 ± 2.4*	53.5 ± 4.1‡	52.8 ± 3.2*	58 ± 12‡	190 ± 36*	2,811 ± 692*	7,229 ± 884*	2,573 ± 425*
+SDI	52.6 ± 3.7‡	52.8 ± 3.9*	57.6 ± 1.5lI	62 ± 12#	213 ± 48*	14,442 ± 2,290*§	1,163 ± 435§¶	2,292 ± 535*♦
+ARI	51.8 ± 5.0†	55.0 ± 4.1‡	57.4 ± 3.3lI	78 ± 15lI	178 ± 41*	85 ± 16*§	758 ± 148‡§	4,284 ± 1,379lI

Also shown are sciatic nerve endoneurial blood flow (BF) and VAP (μg plasma/g/min) and sciatic nerve sorbitol, fructose, and myoinositol levels after 4 weeks of treatment. Data are expressed as mean ± SD for nine to 10 animals.

Different from Controls: *p ≤ 0.001, ^†p ≤ 0.005, ^†p ≤ 0.034.

Different from Diabetics: ^§p ≤ 0.001, ^lIp ≤ 0.01.

Different from ARI-Rx Diabetics: ^♦p < 0.001, ^#p < 0.01, ^¶p < 0.02.